Isotechnika gets Chinese nod for Helicobacter pylori kit:
This article was originally published in Clinica
Executive Summary
Canada's Isotechnika has received approval in China to sell its Helikit, a noninvasive, non-radioactive breath test kit for Helicobacter pylori. The Edmonton, Alberta firm says it now holds two licences for the importation of the Helikit into China, with additional licences held in Canada, Hong Kong, Korea, Mexico and Taiwan. It has also secured a Taiwan-based distributor for Taiwan, China, and Hong Kong, called Success Vision Biotek. As part of the agreement, the distributor will purchase a minimum of 180,000 kits over a three-year period. An order for 12 Isomax point-of-care analysers for use with the Helikit has also been placed and is expected to be filled by the end of the year, Isotechnika adds.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.
EU Must Crack Down Harder On Fake Medical Devices, Says Innovator
Counterfeit copies of LifeVac Europe’s anti-choking devices have been registered on the EU’s EUDAMED database and continue to be sold on third-party platforms. Medtech Insight asked director of sales and marketing Matthew Banagan how the company deals with fake devices and what the authorities must do.